Products - Peritoneal cancer | Topic | NICE

Showing 6 products

Date | Title

Status: Awaiting developmentRemove ‘Status: Awaiting development’ filter

Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6311]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC